Certara (NASDAQ:CERT) Shares Gap Up - What's Next?

Certara, Inc. (NASDAQ:CERT) saw its shares move upward before the market opened on Friday. The stock had finished the previous trading day at $14.25, but opened significantly higher at $15.18. As of the last trade, Certara's shares were priced at $15.15, with a trading volume of 689,656 shares.

Analysts Set New Price Targets

Recently, several research analysts have shared their insights on Certara. Barclays adjusted their target price, lowering it from $14.00 to $12.00, while maintaining an "equal weight" rating on November 7th. Robert W. Baird also revised their target price for Certara, decreasing it from $18.00 to $13.00 and assigning a "neutral" rating in a report dated November 5th. Overall, six investment analysts have given Certara a hold rating, and two analysts have rated the stock as a buy. Data from MarketBeat.com indicates that the stock has an average rating of "Hold" with an average target price of $15.92.

Certara Stock Performance

Certara's stock has recently increased by 2.3%. The company has a 50-day moving average price of $12.03 and a 200-day moving average price of $11.73. Certara’s market capitalization stands at $2.35 billion. The stock shows a price-to-earnings ratio of -72.95 and a price-to-earnings-growth ratio of 9.33 with a beta of 1.57. Additionally, its quick ratio and current ratio are both 2.86, while its debt-to-equity ratio is 0.28.

Institutional Inflows and Outflows

Institutional investors have been active regarding their shares in Certara. For example, Venturi Wealth Management LLC amplified its holdings in Certara by a remarkable 839.1% during the last quarter, now owning 2,808 shares valued at approximately $30,000 after purchasing an additional 2,509 shares. Wells Fargo & Company MN also increased their stake by 48.4% in the fourth quarter, now owning 3,208 shares valued at around $34,000. Other prominent investors like Blue Trust Inc. and KBC Group NV have similarly boosted their stakes significantly in the company. Currently, hedge funds and institutional investors hold about 73.96% of Certara's stock.

About Certara

Certara, Inc. provides a range of software products and technology-enabled services aimed at biosimulation in various stages of drug development. This includes drug discovery, preclinical and clinical research, as well as regulatory submissions and market access, both in the United States and internationally. Certara's services include model-informed drug development and biosimulation solutions that predict pharmacokinetics and pharmacodynamics.

Conclusion

With Certara's stock recently gapping up and analysts reevaluating price targets, investors may ponder what lies ahead for this bio-simulation leader.

Certara, Stocks, Trading